Elsevier Global Medical News -- A Food and Drug Administration advisory panel on July 29 voted 7 to 6 that a specific hemodynamic measure of response to drugs approved for pulmonary arterial hypertension in adults could be used to demonstrate the drugs’ efficacy in children with the disease, and to determine dosing in children.
